{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-099534","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2025-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.435984+00:00","generated_at":"2026-05-17T03:46:39.917098+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aprea sets ATRN-119 RP2D at 1,100 mg QD; pauses monotherapy; prioritizes WEE1 inhibitor APR-1051","bullets":["RP2D of 1,100 mg once daily identified for ATRN-119 from ABOYA-119 Phase 1/2a study.","Further enrollment paused in both QD and BID monotherapy arms; currently-dosed patients continue without interruption.","Considering combination with radiation (HPV+ head & neck), ADCs, and checkpoint inhibitors; discussions with academic centers.","Lead WEE1 inhibitor APR-1051 advancing; Phase 1 data expected at AACR-NCI-EORTC conference on Oct 24, 2025.","ATRN-119 showed durable disease stabilization, manageable AEs, dose-proportional PK at RP2D."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-099534","json":"https://secwatch.observer/filing/0001104659-25-099534.json","markdown":"https://secwatch.observer/filing/0001104659-25-099534.md","text":"https://secwatch.observer/filing/0001104659-25-099534.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465925099534/0001104659-25-099534-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465925099534/apre-20251015x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:46:39.917098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}